Patent ID: 11896614
Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. A method of making an immune effector cell population comprising an immune effector cell comprising a chimeric antigen receptor (“CAR”), comprising acquiring a human immune effector cell population from a pediatric subject having a leukemia, wherein the subject has not been treated with cyclophosphamide or cytarabine,
thereby making an immune effector cell population suitable for use in a CAR therapy, wherein the acquired immune effector cell population includes:
(a) one or more of at least 20% naïve T cells, at least 2% stem central memory T cells, and at least 4% central memory T cells;
(b) at least 50% central memory T cells;
(c) less than 55% effector memory and terminal effector T cells combined; or
(d) two or more of (a), (b) and (c), wherein the combined percentages of the two or more of (a), (b), and (c) do not yield a percentage that exceeds 100%; and
wherein the method further comprises introducing into the immune effector cell population a nucleic acid encoding a CAR; and
wherein the immune effector cell population shows an increase in one or more of: (i) ex-vivo expansion of the immune effector cell population, (ii) the efficacy of the immune effector cell population for therapy, or (iii) the yield of the immune effector cell population, relative to a population of immune effector cells acquired from a pediatric subject having a leukemia who has been treated with cyclophosphamide or cytarabine.